Top Stories
-
Columbia University’s Eleanor and Lou Gehrig ALS Center provided a new treatment called tofersen for a unique genotype, SOD1.
-
A moving documentary involving Columbia Neurologist Dr. Jinsy Andrews follows ALS patient Brian Wallach and his wife, Sandra Abrevaya, as they nspire others impacted by ALS to effect meaningful change
-
Neil Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders and Director of the Eleanor & Lou Gehrig ALS Center, received $15M grant from NIH to design drugs for rare forms of ALS
-
Neil A. Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders, is the principal investigator on the grant that will help develop drugs for an underserved portion of ALS patients.
Topic
Latest News
- January 15, 2024
Neil A. Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders in Neurology, comments on one of the largest state appropriations for research into the neurodegenerative disease.
Topic
- October 10, 2023
Matthew B. Harms, MD and Jinsy Andrews, MD, MSc, associate professors of neurology, explain various aspects of ALS. Laura E. Donovan, MD, assistant professor of neurology, talks about GBM
Topic
- September 21, 2023
Matthew B. Harms, MD, Associate Professor of Neurology, and Neil A. Shneider, MD, PhD, Claire Tow Associate Professor of Motor Neuron Disorders (in Neurology) comment on ALS research
Topic
- May 16, 2023
Neil Shneider, MD, PhD, Claire Tow Associate Professor of Neurology, talks about the new approved tofersen (Qalsody), the first drug developed for patients with a rare form of ALS
Topic
- April 11, 2023
Dr. Jinsy Andrews, associate professor of neurology at CUIMC, commented on the newly approved oral drug to treat amyotrophic lateral sclerosis (ALS), a nervous system disease that weakens muscles
- September 29, 2022
The Food and Drug Administration on Thursday overcame doubts from agency scientists and approved a fiercely debated drug for ALS
- September 9, 2022
Jinsy Andrews, an associate professor in the Department of Neurology at the Vagelos College of Physicians and Surgeons, speaks about the big difference between Aduhelm and AMX0035.
- May 10, 2022
A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Topic
- January 24, 2022
An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is now being tested in ALS patients
- October 19, 2021
Announcing The Project ALS Research Advisory Board
